 Home > Medical News > Medicines Company News > BeiGene will announce a number of clinical and preclinical data at the 2021 annual meeting of the American Association for Cancer Research

BeiGene will announce a number of clinical and preclinical data at the 2021 annual meeting of the American Association for Cancer Research

 Last Update: 2021-07-19
 Source: Internet
 Author: User

Tags

melanin skin cancer

thermal therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Oral report

Title :	Results from RATIONALE 303: A global Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic NSCLC RATIONALE 303 clinical trials: one hundred Chak ^® contrast docetaxel for locally advanced or metastatic NSCLC world's second- or third-line treatment of patients 3 Study
Report No #:	CT039
Sub-venue title:	Disease-Oriented Innovative Clinical Research and Trials Innovative clinical research and trials for disease
Date and time:	Monday, April 12th, 1:30 pm to 3:15 pm Eastern Time (Tuesday, April 13th, 1:30 am to 3:15 am, Beijing time)
Reporter:	Professor Zhou Caicun (Shanghai Pulmonary Hospital)

Title :	Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC) Sitravatinib joint one hundred Chak ^® (for advanced platinum-resistant ovarian cancer PROC security) patients / tolerability and preliminary anti-tumor activity
Report No #:	CT013
Sub-venue title:	Targeted Therapy and Ovarian Cancer Trials Targeted therapy and ovarian cancer clinical trials
Date and time:	US Eastern Time, Sunday, April 11, from 2 pm to 3:45 pm (Beijing time, Monday, April 12, from 2 am to 3:45 am)
Reporter:	Jeffrey Goh Bachelor of Medicine and Bachelor of Surgery (Icon Cancer Center Australia)

Title :	Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study sitravatinib joint one hundred Chak ^® for the PD-1 / PD-L1security refractory or non-remission therapy of unresectable or metastatic melanoma patients / tolerability and preliminary anti-tumor activity 1b Study
Report No #:	CT035
Sub-venue title:	Clinical Trials with Novel Immuno-Oncology Strategies Clinical trials of novel immunological strategies
Date and time:	Sunday, April 11, 4pm-5:45pm, US Eastern Time (4am-5:45am, Monday, April 12th, Beijing time)
Reporter:	Professor Cui Chuanliang (Beijing Cancer Hospital)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.